Sun Pharma Ltd. India’s largest drugmaker, reported June quarter results on Thursday, July 31.
The company’s sales from the US formulations market stood at $473 million, which is in-line with the CNBC-TV18 poll of $476 million. On a year-on-year basis, the US sales grew by 1.4%.
Sun Pharma’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 19.2% from last year to ₹4,302 crore, which is higher than the CNBC-TV18 poll of ₹3,77 crore.
EBITDA margin for the quarter expanded by 250 basis points to 31% from 28.5% last year.
Sun Pharma’s net profit for the quarter fell to ₹3,172.7 crore from ₹3,423.5 crore. The profit was impacted by a one-time cost of ₹818 crore.
Shares of Sun Pharma fell from the highs of the day, currently trading 0.2% lower at ₹1,730.8.
